Mahomed Jassat, BSc LLB MBA Dip M 

Director and Principal Consultant

Mahomed has over 20 years of commercial experience in biotechnology, medical diagnostics, bioscience research and healthcare. During his career he has worked for Amersham International, The Wellcome Foundation, International Murex Technologies Corporation, ZetaGen and as an independent management consultant to companies including spin-out from Imperial College London, and Medical Research Council / Institute of Neurology. Mahomed has held various senior management positions including Senior Product Manager, Product Group Manager, Senior International Market Segments Manager, International Marketing Manager, affiliate General Manager, Managing Director and CEO. He has taken over a hundred products and product groups from concept to market, has set up scientific and commercial collaborations with companies and institutions worldwide, managed technical and commercial teams, set up distribution channels and run key marketing/PR campaigns. He established sub-Saharan Africa's first ISO 9002 approved large-scale commercial diagnostic manufacturing facility with state of the art laboratories for production, R & D, QA as well as warehousing and administrative offices.


Dr David Whitehouse, BSc PhD.   

Senior Consultant

David is an experienced academic, commercial scientist and manager. He has more than 20 years research experience in the university sector, mostly with the MRC Human Biochemical Genetics Unit in The Galton Laboratory, UCL. His published research includes protein detection, human genetics and genomics and the development of rapid diagnostic tests using monoclonal antibodies. In 2000 he transferred to the commercial sector. As R&D Manager at ZetaGen Ltd he specialized in the development of optical and electrophoretic devices for microbial detection and new approaches to DNA based diagnostics. He is an experienced freelance manager of intellectual property and the prosecution of patent applications in the biotechnological and neurosciences fields. He writes, lectures, and devises presentations and training courses for the commercial and higher/medical education sectors. He has recently edited a book for practitioners and students of Forensic Science (John Wiley & Son, 2007). David holds a BSc in Biology (University of Sussex), a PhD in Genetics (University of Nottingham), is a member of the Genetics Society UK, a Scientific Fellow of the Zoological Society and holds an honorary post at the London School of Hygiene and Tropical Medicine.

John Savin B.Sc. Ph.D. M.B.A.   

Senior Consultant

John has worked in the life sciences and biotech sector for over 25 years. He was in sales and marketing of life science equipment and chemicals as an International Product Manager with Pharmacia Biotech (based in Sweden) and Amersham international before joining Cellmark to develop the European market for the original DNA fingerprinting operations. He subsequently gained wide experience as a Senior Consultant in board level consulting with Glaxo, Zeneca, the MRC and Cabinet Office and DTi looking at issues such as the commercialisation of humanised monoclonals and the strategic impact of the human genome project. In 1994 he joined an investment bank as a pharmaceutical and biotech analyst becoming a Director and a top 10 ranked City analyst. In this role, he worked with corporate finance on venture capital, many IPOs, secondary fund raisings, restructuring and due diligence. In 2000 he founded a systems biology company which became Physiomics plc where he was founder CEO. Physiomics entered major collaborations with companies like Bayer and Cyclaceland developed a sophisticated product to optimise cancer therapeutic development. Physiomics listed on AIM in 2004. John now runs a portfolio of projects including interim management, spin out and start up planning and implementation, business development such as product in-licensing, M&A and funding advice and project management in inflammatory disease, cancer and diagnostics. Current areas include gene therapeutics, bio-nanotechnology and stem cells. He also writes commissioned investment research.

Valerie Marshall MA MBA MSI

Senior Associate Consultant

Valerie has an investment and corporate finance background. She invested on behalf of 3i and then the Scottish Development Agency (now Scottish Enterprise) where she made successful investments in start-ups through to public companies, many co-invested with venture capitalists in the UK and US. She then became corporate finance director of stockbroking company Greig Middleton, in charge of IPOs and acting as Nominated Advisor for AIM companies. She is CEO of Stratagem CFS Ltd, which specialises in raising funds for life sciences and technology companies and advising on transactions. She is a non-executive director of various private companies, including 2 spinout companies from Imperial College. Other public sector appointments have included being a Commissioner on the Monopolies and Mergers Commission. She is currently Chair of Council of the University of Kent. Valerie holds an Economics degree from Cambridge University and an MBA from London Business School.

Dr Andrew Wright BSc (Hons) D Phil.

Associate Consultant

Andrew has been working as a patent attorney, specialising in biotechnology, since 1998. He is a registered UK Patent Agent, a European Patent Attorney and an associate of the Chartered Institute of Patent Agents (CIPA). He handles a broad variety of biological and chemical technologies, with particular experience in biotechnology, including genetic engineering, industrial microbiological processes, antibody-based technologies, therapeutic and other medical inventions. He advises on all aspects of patent matters, including the preparation of applications, co ordination of multinational prosecution strategies, European opposition procedures and freedom to operate exercises. Andrew works in Philip Thomas' team at the firm Eric Potter Clarkson (EPC). Philip has over 15 years experience in patenting biotechnology-related inventions, is on the Biotech Committee of CIPA and been awarded a Patent Litigator Certificate. Andrew read molecular biology and biochemistry at Durham University and subsequently obtained a D.Phil from Oxford University.